ADAMS RESPIRATORY THERAPEUTICS FILES LAWSUIT AGAINST MUTUAL PHARMACEUTICALS AND UNITED RESEARCH LABORATORIES FOR INFRINGEMENT OF MUCINEX PATENT

Adams Respiratory Therapeutics, Inc. announced that it has filed a lawsuit in the United States District Court for the District of New Jersey against Mutual Pharmaceuticals Co. and United Research Laboratories, Inc. (URL), both wholly owned subsidiaries of Pharmaceutical Holdings Corp. for infringement of U.S. Patent No. 6,372,252, issued in April 2002. The '252 patent, which is listed in the Orange Book with the Food and Drug Administration (FDA) and expires in 2020, relates to Adams' oral solid, extended-release guaifenesin products. Mucinex and its maximum-strength version, marketed under the Humibid brand name, are the only FDA-approved extended-release expectorant products that provide 12-hour relief from chest congestion in one tablet. Yahoo Finance (http://biz.yahoo.com/prnews/061002/nym122.html?.v=51)